Vidofludimus calcium
Tier C — Watch / tradeVidofludimus calcium
Targets：DHODH
Indications (approved)：Relapsing-remitting multiple sclerosis, Multiple sclerosis, COVID-19, Ulcerative colitis, Sclerosing cholangitis
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| VIDOCa-001 | 57595-25-2 | 2,5-dihydrofuran-3,4-dicarboxylic acid |
| VIDOCa-002 | 867287-99-8 | 3-fluoro-3'-methoxy-[1,1'-biphenyl]-4-amine |
| VIDOCa-003 | 717824-30-1 | 2-((3-fluoro-3'-methoxy-[1,1'-biphenyl]-4-yl)carbamoyl)cyclopent-1-enecarboxylic acid |
| Vidofludimus Calcium | - | - |
Frequently asked questions
What are the approved indications of Vidofludimus calcium?
Approved indications include: Relapsing-remitting multiple sclerosis, Multiple sclerosis, COVID-19, Ulcerative colitis, Sclerosing cholangitis.
When does the Vidofludimus calcium patent expire?
No public expiry year is available for Vidofludimus calcium yet; this page updates once verified.
How many synthesis routes are recorded for Vidofludimus calcium?
1 synthesis routes are recorded; the shortest is 2 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Vidofludimus calcium intermediates?
All intermediates in Vidofludimus calcium routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Vidofludimus calcium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-07